Connect with others who understand.

Sign up Log in
About myPNHteam
Powered By

List of Treatments for Paroxysmal Nocturnal Hemoglobinuria

Below is a listing of treatments and therapies for PNH. Click on one to read more information or connect with others currently using it.

Bkemv (Eculizumab-Aeeb)

Overview
Bkemv is approved by the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis (the destruction of red blood cells). Eligiblility for this…

read more

Bone marrow transplant

Overview
A bone marrow transplant is currently the only cure for paroxysmal nocturnal globunaria (PNH). When someone with PNH develops severe complications such as bone marrow failure, severe aplastic anemia, or… read more

Clinical trials

Overview
Depending on several factors, you may be eligible to participate in clinical trials studying new treatments for paroxysmal nocturnal hemoglobinuria (PNH). Clinical trials are the only way that new treatments… read more

Empaveli (Pegcetacoplan)

Overview
Empaveli is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Empaveli is also known by its drug name, Pegcetacoplan.

read more

Epysqli (Eculizumab-Aagh)

Overview
Epysqli is approved by the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis (breakdown of red blood cells). Before starting this…

read more

Fabhalta (Iptacopan)

Overview
Fabhalta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is also known by its drug name, iptacopan.… read more

PiaSky (Crovalimab-Akkz)

Overview
PiaSky is approved by the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults and children 13 years and older who weigh at least 40 kilograms (around…

read more

Soliris (Eculizumab)

Overview
Soliris is approved by the U.S. Food and Drug Administration (FDA) to treat people with paroxysmal nocturnal hemoglobinuria (PNH). Soliris is prescribed for individuals with PNH to reduce hemolysis (destruction…

read more

Ultomiris (Ravulizumab-Cwv)

Overview
Ultomiris is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people 1 month or older with paroxysmal nocturnal hemoglobinuria (PNH). Ultomiris is also referred to by its… read more

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of Use, and our Health Data and Privacy policies.
Already a Member? Log in